Cidara Therapeutics, Inc. (NASDAQ:CDTX) – Stock analysts at Wedbush lowered their Q3 2017 EPS estimates for Cidara Therapeutics in a research report issued on Monday. Wedbush analyst R. Driscoll now expects that the biotechnology company will earn ($1.01) per share for the quarter, down from their previous estimate of ($0.91). Wedbush currently has a “Outperform” rating and a $13.00 price objective on the stock. Wedbush also issued estimates for Cidara Therapeutics’ Q4 2017 earnings at ($0.76) EPS, Q1 2018 earnings at ($0.78) EPS, Q2 2018 earnings at ($0.79) EPS, Q3 2018 earnings at ($0.80) EPS, Q4 2018 earnings at ($0.59) EPS, FY2018 earnings at ($2.96) EPS, FY2019 earnings at ($2.41) EPS, FY2020 earnings at ($2.48) EPS and FY2021 earnings at ($2.59) EPS.

CDTX has been the subject of a number of other reports. Zacks Investment Research downgraded shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Cantor Fitzgerald started coverage on shares of Cidara Therapeutics in a research report on Monday, June 26th. They issued an “overweight” rating and a $7.00 price target for the company. BTIG Research reiterated a “buy” rating and issued a $20.00 price target (up from $15.00) on shares of Cidara Therapeutics in a research report on Saturday, April 29th. ValuEngine downgraded shares of Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Raymond James Financial, Inc. started coverage on shares of Cidara Therapeutics in a research report on Thursday, April 20th. They issued a “strong-buy” rating and a $14.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Cidara Therapeutics presently has an average rating of “Buy” and a consensus target price of $13.14.

WARNING: “Brokers Issue Forecasts for Cidara Therapeutics, Inc.’s Q3 2017 Earnings (CDTX)” was posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/brokers-issue-forecasts-for-cidara-therapeutics-inc-s-q3-2017-earnings-cdtx/1493972.html.

Shares of Cidara Therapeutics (NASDAQ CDTX) opened at 5.75 on Wednesday. The company’s market capitalization is $96.95 million. Cidara Therapeutics has a 1-year low of $5.60 and a 1-year high of $12.95. The stock has a 50 day moving average price of $7.21 and a 200 day moving average price of $7.43.

Cidara Therapeutics (NASDAQ:CDTX) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.91) by $0.08.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Trexquant Investment LP purchased a new position in shares of Cidara Therapeutics during the second quarter valued at approximately $110,000. Citadel Advisors LLC purchased a new position in shares of Cidara Therapeutics during the second quarter valued at approximately $129,000. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Cidara Therapeutics during the second quarter valued at approximately $131,000. Teachers Advisors LLC increased its position in shares of Cidara Therapeutics by 17.5% in the fourth quarter. Teachers Advisors LLC now owns 16,524 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 2,458 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Cidara Therapeutics during the fourth quarter valued at approximately $173,000. Institutional investors and hedge funds own 68.22% of the company’s stock.

In other news, insider Taylor Sandison acquired 20,000 shares of the stock in a transaction on Wednesday, June 7th. The stock was acquired at an average cost of $5.90 per share, for a total transaction of $118,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeffrey Stein acquired 15,000 shares of the stock in a transaction on Monday, June 5th. The shares were purchased at an average price of $5.95 per share, with a total value of $89,250.00. The disclosure for this purchase can be found here. 18.90% of the stock is owned by insiders.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Earnings History and Estimates for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.